Compass Therapeutics (CMPX) vs Humacyte (HUMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Humacyte (HUMA) has outperformed Compass Therapeutics (CMPX) over the past year, losing 63.5% versus a loss of 85.9%. Over five years, CMPX leads with a -78.6% price change compared with -95.9% for HUMA. Compass Therapeutics is the larger company by market cap ($123.9 million vs $123.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMPX | HUMA |
|---|---|---|
| Share price | $0.6882 | $0.4454 |
| Market cap | $123.94M | $123.73M |
| 1-day change | +1.43% | -17.90% |
| YTD return | -87.18% | -53.65% |
| 1-year return | -85.87% | -63.49% |
| 5-year return | -78.63% | -95.94% |
| EPS (TTM) | $-0.46 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $2.04M |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-66.49M | $-40.83M |
| Gross margin | — | -376.05% |
| Operating margin | — | -5306.04% |
| Net margin | — | -2003.58% |
| 52-week high | $6.88 | $1.53 |
| 52-week low | $0.57 | $0.337 |
| Distance from 52-week high | -90.00% | -70.79% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +664.31% | +268.21% |
| Average volume | 3.88M | 5.36M |
| Shares outstanding | 180.09M | 277.80M |
| Employees | 39 | 184 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HUMA has outperformed CMPX by 22.4 percentage points over the past year.
About Compass Therapeutics
CMPX stock →Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
About Humacyte
HUMA stock →Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 184 employees
CMPX vs HUMA FAQ
Which is bigger, Compass Therapeutics or Humacyte?
Compass Therapeutics (CMPX) is larger, with a market capitalization of $123.94M compared with $123.73M for Humacyte (HUMA).
Which stock has performed better over the past year, CMPX or HUMA?
HUMA returned -63.49% over the past 12 months, compared with -85.87% for CMPX (price return, excluding dividends). Past performance does not predict future results.
Are Compass Therapeutics and Humacyte in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.